Insmed, Inc. $INSM Stock Position Raised by Neo Ivy Capital Management

Neo Ivy Capital Management boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 287.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,256 shares of the biopharmaceutical company’s stock after acquiring an additional 12,804 shares during the quarter. Neo Ivy Capital Management’s holdings in Insmed were worth $1,737,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of INSM. Mutual of America Capital Management LLC lifted its stake in shares of Insmed by 2.7% in the 1st quarter. Mutual of America Capital Management LLC now owns 79,141 shares of the biopharmaceutical company’s stock valued at $6,038,000 after purchasing an additional 2,093 shares during the last quarter. CWM LLC increased its position in Insmed by 24.5% during the first quarter. CWM LLC now owns 2,052 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 404 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in Insmed during the first quarter valued at about $975,000. Allianz Asset Management GmbH lifted its position in shares of Insmed by 4.9% in the first quarter. Allianz Asset Management GmbH now owns 75,284 shares of the biopharmaceutical company’s stock worth $5,743,000 after buying an additional 3,534 shares during the last quarter. Finally, KLP Kapitalforvaltning AS lifted its position in shares of Insmed by 3.6% in the first quarter. KLP Kapitalforvaltning AS now owns 34,200 shares of the biopharmaceutical company’s stock worth $2,609,000 after buying an additional 1,200 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on INSM. Evercore ISI reissued an “outperform” rating and issued a $180.00 price objective on shares of Insmed in a research note on Wednesday, October 1st. JPMorgan Chase & Co. increased their price target on Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Wednesday, October 8th. UBS Group upped their price objective on shares of Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, William Blair initiated coverage on shares of Insmed in a research note on Wednesday, August 20th. They issued an “outperform” rating on the stock. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and a consensus target price of $175.53.

Insmed Stock Down 1.9%

INSM opened at $199.64 on Friday. The business has a 50 day moving average of $166.68 and a 200-day moving average of $123.91. The stock has a market capitalization of $42.58 billion, a price-to-earnings ratio of -34.96 and a beta of 1.05. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $208.00.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same quarter in the previous year, the company earned ($1.27) earnings per share. Insmed’s revenue for the quarter was up 52.4% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other news, insider Michael Alexander Smith sold 27,130 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the completion of the transaction, the insider owned 54,902 shares of the company’s stock, valued at approximately $10,089,889.56. This represents a 33.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Elizabeth M. Anderson sold 10,000 shares of the stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the completion of the sale, the director owned 63,729 shares of the company’s stock, valued at approximately $12,482,599.23. The trade was a 13.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 252,922 shares of company stock worth $43,533,383. Insiders own 3.00% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.